bioRxivImmunologyPreprint
Interruption of the Intratumor CD8:Treg Crosstalk Improves the Efficacy of PD-1 Immunotherapy
S. N. Geels, A. Moshensky, R. S. Sousa, B. L. Walker, R. Singh, G. Gutierrez, M. Hwang, T. R. Mempel, Q. Nie, S. Othy, F. Marangoni
Abstract
PD-1 blockade unleashes the potent antitumor activity of CD8 cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen response to immunotherapy. Tumor Treg inhibition is a promising strategy to overcome therapeutic resistance; however, the mechanisms supporting tumor Tregs during PD-1 immunotherapy are largely unexplored. Here, we report that PD-1 blockade increases tumor Tregs in mouse models of immunogenic tumors, including melanoma, and metastatic melanoma patients. Unexpectedly, Treg accumulation was not caused by Treg-intrinsic inhibition of PD-1 signaling but instead depended on an indirect effect of activated CD8 cells. CD8 cells colocalized with Tregs within tumors and produced IL-2, especially after PD-1 immunotherapy. IL-2 upregulated the anti-apoptotic protein ICOS on tumor Tregs, causing their accumulation. ICOS signaling inhibition before PD-1 immunotherapy resulted in increased control of immunogenic melanoma. Thus, interrupting the intratumor CD8:Treg crosstalk is a novel strategy that may enhance the efficacy of immunotherapy in patients.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell-cell communication
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrating Mathematical and Mouse Models Identifies T regulatory Cell Influx as a Key Determinant of Acquired Resistance to PD-1 Immunotherapy
Rachel S Sousa, Shannon N Geels, … Francesco Marangoni·Cancer ResearchPeer-reviewed·Aug 20, 2026
- Dendritic cell PD-L2 restrains intratumoral CD8+ T cell immunity
Jinwoo Nah, Amanda Sun, … Chrysothemis C. Brown·bioRxiv·Sep 16, 2026
- Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
A. Gangaev, E. A. Rozeman, … P. Kvistborg·bioRxiv·Dec 15, 2020
- Myeloid DC-SIGN drives tumor immune evasion and resistance to PD-1 blockade through ICAM-2-ERM-mediated T-cell mechanosuppression
- Defining the mechanisms of action and resistance to the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain models
M. Phadke, J. Li, … K. S. Smalley·bioRxiv·Apr 14, 2023
- Tumor PD-L1 selectively suppresses type I interferon in myeloid cells to suppress CTL recruitment to promote lung metastasis
J. D. Klement, P. S. Redd, … K. Liu·bioRxiv·Jun 18, 2021